Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2206741 | 0.87 | TSHR (0.58) | CNR1CNR2TSHRCYP2D6PPARG | |
| SCHEMBL19291600 | 0.85 | CYP2D6 (0.55) | CNR1CNR2TSHRCYP2D6TAAR1 | |
| SCHEMBL4569094 | 0.85 | TAAR1 (0.51) | CNR1CNR2TSHRCYP2D6TAAR1 | |
| SCHEMBL14640150 | 0.85 | TAAR1 (0.54) | CYP2D6TAAR1PPARGPPARA | |
| SCHEMBL2208231 | 0.84 | TDP1 (0.51) | KCNH2L3MBTL1 | |
| SCHEMBL8903123 | 0.84 | CYP2D6 (0.50) | CNR1CNR2TSHRCYP2D6TAAR1 | |
| SCHEMBL29929316 | 0.84 | TAAR1 (0.58) | TSHRTAAR1KDM4E | |
| SCHEMBL21657447 | 0.84 | TAAR1 (0.58) | TSHRTAAR1KDM4E | |
| SCHEMBL2206320 | 0.84 | TAAR1 (0.54) | CYP2D6TAAR1KDM4EMAPK1GGPS1 | |
| SCHEMBL20332570 | 0.83 | KCNA3 (0.53) | TAAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CNR1 2205/4885CNR2 2231/4885TSHR 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.